SESSION TITLE: Lung Cancer Posters II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: In patients with lung cancer, the incidence of venous thromboembolism (VTE) is reported to be about 3%. Metastatic disease has been reported to be a risk factor of VTE in lung cancer patients. Incidence of VTE in metastatic lung cancer has not been studied. Effect of comorbid conditions on the occurrence of VTE in these patients is not known. The objective of this study was was: (1) To determine the incidence of VTE in patients with metastatic lung cancer. (2) To determine whether the presence of specific comorbid conditions, age and tumor histology increase the risk of VTE in these patients.
METHODS: Medical Records of patients with advanced lung cancer (Stage 4)) being treated at our institution’s cancer center over the last 3 years was reviewed. Patient demographics, type of lung cancer and the presence of following comorbid conditions were noted: Congestive heart failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), Diabetes mellitus (DM), Coronary Artery Disease, Cerebrovascular Disease (CVD), Chronic Renal Failure (CRF), Connective tissue disease (CTD) and Chronic liver disease (CLD). Number of patients developing VTE was determined. Multivariate logistic regression analysis was performed to determine whether the above comorbidities were associated with the occurrence of VTE in these patients. p < 0.05 was deemed statistically significant.
RESULTS: Seventy-two patients were studied; mean age was: 70 ± 13 years; 49% were males. Seventy-three percent had adenocarcinoma. 12% had squamous cell and 15% had small cell cancer. Twenty-three percent patients had COPD; 12% had CRF; 12% had CHF; 9% had CVD; 5% had CLD; 4% had CAD and 4% had CTD. Twenty percent of studied patients had a VTE. On multivariate analysis, none of the studied variables, were found to have a significant correlation with the occurrence of VTE.
CONCLUSIONS: The incidence of VTE is significantly high in patients with advanced lung cancer. Though the number of chronic medical comorbidities has been reported to increase the risk of VTE in lung cancer, the specific comorbid conditions do not individually increase the risk. Risk of occurrence of VTE does not increase with age, type of lung cancer, or the presence of specific individual comorbid conditions in patients with metastatic lung cancer.
CLINICAL IMPLICATIONS: Incidence of VTE is higher in metastatic lung cancer and risk factors associated with this merits studies in larger group of patients.
DISCLOSURE: The following authors have nothing to disclose: Natalie Berger, Susan Tannenbaum, D. Datta
No Product/Research Disclosure Information